Company: INDP
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010099
Chunk: 45

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 1
Chunk 45
---
219,698  
     76.7%
  
    General and administrative 
     1,761,719  
     2,352,097  
     (590,378) 
     (25.1)%

    Total operating expenses 
     4,572,559  
     3,943,239  
     629,320  
     16.0%

    Loss from operations 
     (4,572,559) 
     (3,943,239) 
     (629,320) 
     16.0%

    Other income, net 
     40,129  
     136,562  
     (96,433) 
     (70.6)%

    Net loss 
    $(4,532,430) 
    $(3,806,677) 
    $(725,753) 
     19.1%
  
    Net loss attributable
    to common stockholders per share, basic and diluted 
    $(0.32) 
    $(0.45) 
    $0.13  
     (28.9)%
  
    Weighted average number
    of shares used in calculating net loss per share, basic and diluted 
     14,102,378  
     8,442,364  

3

Research
and Development Expenses

Our
research and development expenses for the three months ended March 31, 2025 amounted to approximately $2.8 million, an increase of approximately
$1.2 million, or approximately 76.7%, compared to approximately $1.6 million for the three months ended March 31, 2024. This increase
was attributable primarily to an increase of approximately $1.5 million in costs associated with our Phase 1 clinical trial and
was offset by a decrease of approximately $0.3 million in payroll and related expenses.

General
and Administrative Expenses

Our
general and administrative expenses for the three months ended March 31, 2025 amounted to
approximately $1.8 million, a decrease of approximately $0.6 million, or approximately 25.1%, compared to approximately $2.4 million
for the three months ended March 31, 2024. This decrease was attributable primarily to a decrease
in payroll and related expenses and in legal fees.

Other
Income, Net

During
the three months ended March 31